Making Minutes Matter with VALTOCO® (diazepam nasal spray)
Registration:
Tuesday, May 12, 12:00 PM EST
(9:00 AM PST)
Presented by:
Nancy Santilli, PNP, MN, FAAN
Epilepsy Consultant
Sunnyvale, CA
Brittani Ireland, DNP
Patient Services Manager;
Pediatric Nurse Practitioner
Neurelis, Inc.
Memphis, TN
Esteban G
Patient Ambassador with
episodes of frequent
seizures
Danielle L
Patient Ambassador with
episodes of frequent
seizures
Register:
TERMS AND CONDITIONS
By providing your name, address, and other personal information above and clicking the SUBMIT button below, you agree to permit Neurelis and others working on behalf of Neurelis to use this information to provide you with information, resources, services, communications, and/or marketing materials about VALTOCO, and disease-related materials. Additionally, your information may be used for market research purposes.
At any time, you can request a copy of this permission and that personal information about you be removed from the contact list for VALTOCO by calling 866-696-3873 or via email at [email protected]. Unless you change this selection sooner, your permission will expire one (1) year after Neurelis ceases to sell VALTOCO. If you have subscribed to receive updates through any other channel, you must unsubscribe through their platform should you no longer wish to be contacted.
Indication
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
IMPORTANT SAFETY INFORMATION
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
- The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.
- The continued use of benzodiazepines may lead to clinically significant physical dependence. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening.
Adverse Reactions
The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.
To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch)
Please see full Prescribing Information, including Boxed Warning.
US-PRC-25-00262-v2 04/2026